Lv4
468 积分 2026-07-08 加入
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
11小时前
待确认
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD
12小时前
已完结
IL-6 as a marker for NMOSD disease activity
1个月前
已完结
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
1个月前
已完结
Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience
1个月前
已完结
Interleukin 6: at the interface of human health and disease
1个月前
已完结
Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab
1个月前
已完结
补体抑制剂治疗视神经脊髓炎谱系疾病的新进展
1个月前
已完结
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD
1个月前
已完结
Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study
1个月前
已完结
皖公网安备34019202002308
